"Chesapeake Urology is the largest, fully-integrated urology practice in Maryland and the Mid-Atlantic region, providing a comprehensive array of urologic services to patients. Our staff of more than 800 professionals, including more than 80 urologists and fellowship-trained specialists, focus on what’s most important to patients – superior and personalized care, an innovative approach to the most advanced diagnostics, leading-edge treatments, and clinical trials, as well as positive outcomes. At Chesapeake Urology, we’re dedicated to providing the most personal care for life’s most personal issues."

During the past decade, Chesapeake Urology Research Associates conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 12 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 6 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chesapeake Urology Research Associates" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Carolina Research Professionals, LLC" with 3 trials sponsored, "Dendreon" with 3 trials sponsored, "Veru Inc." with 3 trials sponsored and "Bioniche Life Sciences Inc." with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chesapeake Urology Research Associates" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator, "Parexel" with 2 trials as a collaborator and "CareFirst BlueCross BlueShield" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Chesapeake Urology Research Associates" are "Prostate Cancer" (12 trials), "Benign Prostatic Hyperplasia" (2 trials), "Cancer of the Prostate" (2 trials), "Metastatic Castrate Resistant Prostate Cancer (mCRPC)" (2 trials) and "Prostate Cancer Metastatic" (2 trials). Many other conditions were trialed in "Chesapeake Urology Research Associates" in a lesser frequency.

Most popular intervention types in "Chesapeake Urology Research Associates" are "Drug" (28 trials), "Other" (6 trials), "Biological" (5 trials), "Device" (4 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Enzalutamide" (3 trials), "Prednisone" (3 trials), "Abiraterone Acetate" (2 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Chesapeake Urology Research Associates" are 34 trials for "Male" genders and 10 trials for "All" genders.

Currently, there are NaN active trials in "Chesapeake Urology Research Associates". undefined are not yet recruiting, 10 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Chesapeake Urology Research Associates, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Chesapeake Urology Research Associates, 7 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".